227 related articles for article (PubMed ID: 20066509)
1. Reconstitution of self-tolerance after hematopoietic stem cell transplantation.
Hess AD
Immunol Res; 2010 Jul; 47(1-3):143-52. PubMed ID: 20066509
[TBL] [Abstract][Full Text] [Related]
2. Immune tolerance to self-major histocompatibility complex class II antigens after bone marrow transplantation: role of regulatory T cells.
Hess AD; Thoburn CJ
Biol Blood Marrow Transplant; 2006 May; 12(5):518-29. PubMed ID: 16635787
[TBL] [Abstract][Full Text] [Related]
3. Modulation of graft-versus-host disease: role of regulatory T lymphocytes.
Hess AD
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):13-21. PubMed ID: 16399597
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulating functions of human leukocyte antigen-G and its role in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Bu X; Zhong J; Li W; Cai S; Gao Y; Ping B
Ann Hematol; 2021 Jun; 100(6):1391-1400. PubMed ID: 33709198
[TBL] [Abstract][Full Text] [Related]
6. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
Kline J; Subbiah S; Lazarus HM; van Besien K
Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
[TBL] [Abstract][Full Text] [Related]
7. Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells.
Monlish DA; Beezhold KJ; Chiaranunt P; Paz K; Moore NJ; Dobbs AK; Brown RA; Ozolek JA; Blazar BR; Byersdorfer CA
JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34291733
[TBL] [Abstract][Full Text] [Related]
8. Understanding the alloresponse: new approaches to graft-versus-host disease prevention.
Teshima T; Ferrara JL
Semin Hematol; 2002 Jan; 39(1):15-22. PubMed ID: 11799525
[TBL] [Abstract][Full Text] [Related]
9. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
Yang K; Fan ZP; Liu QF; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic Dysfunction during Graft-Versus-Host Disease: A Self-Destructive Process?
Müskens KF; Lindemans CA; Belderbos ME
Cells; 2021 Aug; 10(8):. PubMed ID: 34440819
[TBL] [Abstract][Full Text] [Related]
11. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
12. Colonic graft-vs.-host disease in autologous versus allogeneic transplant patients: earlier onset, more apoptosis, and lack of regulatory T-cell attenuation.
Hartley CP; Carrillo-Polanco LF; Rowan DJ; Hagen CE
Mod Pathol; 2018 Oct; 31(10):1619-1626. PubMed ID: 29899549
[TBL] [Abstract][Full Text] [Related]
13. Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide.
Hess AD; Bright EC; Thoburn C; Vogelsang GB; Jones RJ; Kennedy MJ
Blood; 1997 Mar; 89(6):2203-9. PubMed ID: 9058745
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive Analysis of the Activation and Proliferation Kinetics and Effector Functions of Human Lymphocytes, and Antigen Presentation Capacity of Antigen-Presenting Cells in Xenogeneic Graft-Versus-Host Disease.
Kawasaki Y; Sato K; Hayakawa H; Takayama N; Nakano H; Ito R; Mashima K; Oh I; Minakata D; Yamasaki R; Morita K; Ashizawa M; Yamamoto C; Hatano K; Fujiwara SI; Ohmine K; Muroi K; Kanda Y
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1563-1574. PubMed ID: 29678638
[TBL] [Abstract][Full Text] [Related]
15. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.
Alho AC; Kim HT; Chammas MJ; Reynolds CG; Matos TR; Forcade E; Whangbo J; Nikiforow S; Cutler CS; Koreth J; Ho VT; Armand P; Antin JH; Alyea EP; Lacerda JF; Soiffer RJ; Ritz J
Blood; 2016 Feb; 127(5):646-57. PubMed ID: 26670634
[TBL] [Abstract][Full Text] [Related]
16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic bone marrow grafts with high levels of CD4(+) CD25(+) FoxP3(+) T cells can lead to engraftment failure.
Fricke S; Rothe K; Hilger N; Ackermann M; Oelkrug C; Fricke C; Schönfelder U; Niederwieser D; Emmrich F; Sack U
Cytometry A; 2012 Jun; 81(6):476-88. PubMed ID: 22522779
[TBL] [Abstract][Full Text] [Related]
18. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis.
Slavin S; Nagler A; Varadi G; Or R
Exp Hematol; 2000 Jul; 28(7):853-7. PubMed ID: 10907647
[TBL] [Abstract][Full Text] [Related]
19. Infusion of endothelial progenitor cells accelerates hematopoietic and immune reconstitution, and ameliorates the graft-versus-host disease after hematopoietic stem cell transplantation.
Zeng L; Chen C; Song G; Yan Z; Xu S; Jia L; Ding S; Cao J; Chen W; Cheng H; Li Z; Sang W; Wang L; Li Y; Xu K
Cell Biochem Biophys; 2012 Dec; 64(3):213-22. PubMed ID: 22806343
[TBL] [Abstract][Full Text] [Related]
20. Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic.
Gu G; Yang JZ; Zhang JQ; Sun LX
Cell Immunol; 2019 Dec; 346():103991. PubMed ID: 31607390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
